A clinical trial to study the effects and safety of two drugs, Lurasidone and olanzapine in patients with Schizophrenia
Not Applicable
Completed
- Conditions
- Health Condition 1: F20- Schizophrenia
- Registration Number
- CTRI/2022/04/041843
- Lead Sponsor
- Alok Gupta
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 114
Inclusion Criteria
Patients giving informed consent, diagnosed with Schizophrenia as per ICD 10 diagnostic criteria and drug free for atleast 8 weeks.
Exclusion Criteria
Known case of diabetes mellitus, dyslipidemia and cardiac illness. Systemic or neurological Disorder affecting cognition, behavior or mental status.
Substance dependence except nicotine and caffeine within the past month of entering the study.Long standing medical or surgical illness and patients with mental retardation or organic brain disease.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Positive and Negative Syndrome Scale, Brief Psychiatric Rating Scale, Clinical Global Impressions Scale â?? Impressions and Montreal Cognitive Assessment would be used to assess change in symptoms of Schizophrenia.Timepoint: At the time of enrollment in the study and at the end of 6 weeks.
- Secondary Outcome Measures
Name Time Method ipid Profile, Fasting Blood Sugar, Post Postprandial Blood Sugar and ECG would be done to assess change in cardio metabolic parameters in the patients.Timepoint: At the time of enrollment in the study and at the end of 6 weeks.